Trial Profile
A phase IV, open, randomized, controlled study to demonstrate the non-inferiority of co-administration of GSK Biologicals live attenuated measles-mumps-rubella-varicella vaccine and Baxter's Neisseria meningitidis C conjugate vaccine versus separate administration of each of the vaccines in healthy children aged 12 through 23 months.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group C conjugate (Primary) ; MMR-varicella zoster virus vaccine (Primary)
- Indications Chickenpox; Measles; Meningococcal group C infections; Mumps; Neisseria infections; Rubella; Varicella zoster virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline Biologicals; GSK
- 06 Aug 2011 New trial record